STIL

Across TCGA pan-cancer cohorts, STIL Mutation is linked to patient survival in 7 of 34 cancer types, making it a survival-associated STIL data layer compared with 27 for mass-spec protein and 1 for mass-spec protein.

The strongest signal is observed in bladder urothelial carcinoma (BLCA), where higher STIL Mutation is associated with better overall survival. In most high-consensus cancer types, elevated STIL expression acts as an unfavorable survival marker, although some lineages such as BLCA and UCEC show a favorable association.

BLCA, HNSC, and LUAD are the cancer types where STIL Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
BLCA	OS	Median	III,IV	1.000	0.348	.007	33	view →
HNSC	OS	Median	All	0.162	0.685	.018	24	view →
LUAD	OS	Median	All	0.158	0.835	<.001	24	view →
LUSC	OS	Median	II,III,IV	0.435	0.749	.005	21	view →
UCEC	DFS	Median	All	0.926	0.607	.008	14	view →
ESCA	DFS	Median	II,III,IV	0.187	0.525	.029	12	view →
LIHC	DFS	Median	II,III,IV	0.044	0.427	<.001	6	view →

Pink = unfavorable, green = favorable. Showing the 7 strongest of 7 lineages.

STIL–BLCA (OS)

Open the BLCA breakdown →